Sodium zirconium cyclosilicate for treating hyperkalaemia

Condition

Kidney

19 December 2022

Published on 19 Dec 2022
Last Updated on 19 Dec 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended listing sodium zirconium cyclosilicate on the MOH List of Subsidised Drugs for treating hyperkalaemia due to the uncertain extent of clinical benefit and uncertain cost effectiveness compared with current standard of care.

Sodium zirconium cyclosilicate for treating hyperkalaemia (19 December 2022) [PDF, 133 KB]

PES Sodium zirconium cyclosilicate for treating hyperkalaemia (19 December 2022) [PDF, 115 KB]